{"entity":{"id":"ltz-therapeutics","kind":"company","name":"LTZ Therapeutics","aka":[],"tldr":"LTZ Therapeutics makes two-armed antibodies that bring the immune system's scavenger cells, macrophages, into contact with cancer cells so they eat them. Its first medicines are in early trials in lymphoma and bowel cancer.","summary":"LTZ Therapeutics Inc., with sites in Redwood City, California and Shenzhen, China, develops bispecific myeloid cell engagers on its Universal Myeloid Cell Engager (U-MCE) platform, designed to direct macrophages and other myeloid cells to kill tumour cells and to reset the immunosuppressive tumour microenvironment. LTZ-301 targets CD79b and is in a phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma (NCT07121946), after FDA IND clearance in February 2025. LTZ-232 targets EpCAM; it received FDA IND clearance in July 2026 and the company dosed the first participant in a phase 1/1b trial in metastatic colorectal cancer and other solid tumours in October 2026 (NCT07878988). It has platform collaborations with Eli Lilly (autoimmune disease, July 2025) and GSK (oncology, November 2025). The company was founded in 2022, according to the company, and its May 2026 release puts total funding at about USD 130 million. Its first registered cancer trial, NCT07121946, was posted on ClinicalTrials.gov in August 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.ltztherapeutics.com/"},{"label":"Pipeline","url":"https://www.ltztherapeutics.com/pipeline/index.html"},{"label":"May 2026 USD 38 million financing release","url":"https://www.ltztherapeutics.com/html/news/139.html"},{"label":"ClinicalTrials.gov: phase 1 trial of LTZ-301 (NCT07121946)","url":"https://clinicaltrials.gov/study/NCT07121946"},{"label":"ClinicalTrials.gov: phase 1/1b trial of LTZ-232 (NCT07878988)","url":"https://clinicaltrials.gov/study/NCT07878988"}],"tags":[],"related":[],"cancers":["non-hodgkin-lymphoma","dlbcl","colorectal"],"sections":["immunotherapy"],"technologies":["bispecific-antibody"],"targets":["cd79b","epcam"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year from the company's May 2026 financing release ('since its founding in 2022'), read on 29 October 2026. A July 2024 Series A of 'over $20 million' appears as a headline on the company news page but the release was not read, so no row is recorded. The value of the GSK and Lilly agreements was not read from a primary source and is not recorded. None of the named investors has an OnCo investor record."],"hq":"Redwood City, CA","country":"US","companyType":"biotech","website":"https://www.ltztherapeutics.com/","founded":2022,"stage":"startup","investors":[],"funding":[{"round":"Pre-Series A","year":2022,"amountUsd":17000000,"source":"https://www.ltztherapeutics.com/html/news/36.html","note":"Led by K2 Venture Partners with Qiming Venture Partners and Tigermed"},{"round":"Private financing","year":2026,"amountUsd":38000000,"source":"https://www.ltztherapeutics.com/html/news/139.html","note":"Oversubscribed round led by GL Ventures; the release does not name the round"}]},"route":"/companies/ltz-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"}],"target":[{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/"},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/"}]}}